What happened with TNGX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Tango Therapeutics is developing small-molecule drugs that target weaknesses created by specific genetic changes in cancer cells. It uses biomarkers to identify patients whose tumors have those changes. Its clinical programs include vopimetostat and TNG456, designed to preferentially inhibit a protein that cancers missing the MTAP gene depend on; TNG456 is being developed for cancers in the brain and central nervous system.
Tango has no approved products and has never earned revenue from drug sales. Gilead has supplied most of its revenue through payments for research and licensing rights. The research portion of that collaboration has ended, but Gilead continues work on licensed programs, and agreements for potential milestone payments and royalties remain in place. These are not assured income.
Tango has funded development through equity financing and the Gilead collaboration and expects to need additional funding. Turning its own drug candidates into sales depends on identifying and enrolling eligible patients, demonstrating safety and efficacy in trials, and obtaining regulatory approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
IDEAYA Biosciences could add competition for Tango in drugs for MTAP-deleted cancers, including candidates that block PRMT5. Watch whether IDEAYA’s PRMT5 candidates enter clinical trials; Tango identifies them as potential competitors not yet in trials.
Amgen directly competes with Tango to develop drugs that block PRMT5 in MTAP-deleted cancers. Its Phase 1/2 program uses the same MTA-cooperative mechanism, making its trial results relevant to the competition facing Tango’s vopimetostat and TNG456.
Bristol Myers Squibb’s PRMT5 program, acquired with Mirati, competes with Tango’s drugs for MTAP-deleted cancers. Progress in its Phase 1/2 trials is a direct comparison point for Tango’s vopimetostat and TNG456, which use the same MTA-cooperative mechanism.
Tango depends on Revolution Medicines to supply drugs that block RAS for its trial combining vopimetostat with daraxonrasib or zoldonrasib. Watch supply and combination-trial results in patients with MTAP-depleted, RAS-mutant pancreatic ductal adenocarcinoma or lung cancer; Tango has limited control over the partner drugs’ supply and regulatory status.
Gilead pays for rights to develop Tango-discovered programs, with future milestone and royalty agreements still in effect, but also has a potentially competing MTAP-selective PRMT5 candidate. Watch the licensed programs rather than treating Tango’s 2025 collaboration revenue as recurring: ending the research term triggered recognition of $53.8 million in remaining deferred revenue that year.
AstraZeneca competes with Tango in drugs that block PRMT5 in MTAP-deleted cancers, with both companies’ programs already in clinical development. Its Phase 1/2 results matter more to this rivalry than its existing cancer-drug sales: the competing program uses the same MTA-cooperative mechanism as Tango’s.
Tango depends on Erasca to supply a drug targeting RAS broadly—a pan-RAS molecular glue—for planned testing with vopimetostat. The combination’s safety and efficacy link both development pipelines; Tango must establish each drug’s contribution, not just whether the combination works.
BeOne Medicines competes with Tango for the same MTAP-deleted cancer population through drugs that block PRMT5 using the MTA-cooperative mechanism. Watch its Phase 1/2 program for progress against Tango’s vopimetostat and TNG456, rather than using sales of its leading blood-cancer drug BRUKINSA to judge this rivalry.
Tango depends on Eli Lilly to supply abemaciclib for combination testing with TNG456, its brain-penetrant PRMT5 inhibitor for MTAP-deleted central nervous system cancers. Watch whether supply supports those trials and whether each drug contributes to the combination’s safety and efficacy; Tango has limited control over the partner drug’s supply.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb’s clinical PRMT5 program competes with Tango Therapeutics for patients with MTAP-deleted cancers, so its trial updates will show how strong that competition may be.
Look for clinical progress in Bristol Myers Squibb’s PRMT5 program and compare its stage and target patients with Tango’s vopimetostat and TNG456. Clear progress would mean another clinical option is advancing for the same patient group, raising the pressure on Tango to enroll patients and establish its drugs’ value. Setbacks would ease that competitive pressure, but would not show that Tango’s drugs work.
Gilead Sciences Inc earningsGILD
Gilead Sciences holds rights to programs discovered by Tango Therapeutics, and its development updates can show whether those programs may still generate milestones or royalties for Tango.
Watch Gilead’s development updates on the licensed programs, not its overall results or Tango’s past collaboration revenue. Continued work keeps open the possibility of future milestone payments or sales royalties; stalled or absent progress leaves Tango with less potential funding from the collaboration. Tango’s 2025 collaboration revenue included deferred payments recognized when the research term ended, not a payment that recurs each year.
Eli Lilly & Co. earningsLLY
Eli Lilly supplies abemaciclib for Tango Therapeutics’ TNG456 combination testing, so any supply or development constraint could affect those trials.
Watch for Lilly updates on abemaciclib supply or relevant development, alongside progress in Tango’s TNG456 combination trials. Continued supply and trial progress would mean the combination can keep being tested; constrained supply or a blocked collaboration could delay Tango’s work. Even if the combination shows an effect, the trials must establish whether each drug contributes to safety and efficacy.
Tango Therapeutics, Inc. earningsThis company
Tango Therapeutics has no approved drugs for sale, so its report will show whether its cancer programs are advancing and how quickly the company is spending to develop them.
Read clinical progress alongside operating costs and cash. Progress in programs such as vopimetostat and TNG456, with spending still proportionate to available funds, would support continued testing of those therapies. Limited progress alongside high costs would put funding under greater pressure and increase the need for financing or program cuts. Tango’s 2025 collaboration revenue included deferred payments recognized when the research term ended early, so it should not be treated as recurring income.
Revolution Medicines, Inc. earningsRVMD
Revolution Medicines supplies RAS inhibitors for Tango Therapeutics’ vopimetostat combination trials, so changes in supply or development could affect those cancer studies.
Watch Revolution Medicines’ updates on the relevant RAS drugs alongside Tango’s combination trials in patients with MTAP-deleted, RAS-mutant pancreatic or lung cancer. Continued supply and trial progress would keep this path testable; a supply or development disruption could delay Tango’s studies. Any combination result must still establish what each drug contributes.
Erasca, Inc. earningsERAS
Erasca supplies the pan-RAS molecular glue planned for combination testing with Tango Therapeutics’ vopimetostat, so supply or development changes could impede that work.
Watch Erasca’s development and supply updates on its pan-RAS molecular glue, and whether Tango can advance combination testing with vopimetostat. Continued access and testing would keep this development path open; a supply or development constraint could delay Tango’s plans. Even if the combination shows an effect, its safety and efficacy must be assessed for each drug’s contribution.
